Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
4.270
+0.050 (1.18%)
Aug 30, 2024, 4:00 PM EDT - Market closed
Savara Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
37
Market Cap
702.84M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pacira BioSciences | 690.31M |
Paragon 28 | 235.44M |
Adaptive Biotechnologies | 168.77M |
SI-BONE | 150.71M |
Wave Life Sciences | 110.50M |
CureVac | 70.57M |
Exscientia | 26.57M |
Mereo BioPharma Group | 1.00M |
SVRA News
- 15 days ago - Savara Announces New Employment Inducement Grant - Business Wire
- 16 days ago - Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024 - Business Wire
- 19 days ago - Savara Reports Second Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 2 months ago - Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock - Business Wire
- 2 months ago - Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday? - Benzinga
- 2 months ago - Savara's rare lung disease drug meets main goal in late-stage study - Reuters
- 2 months ago - Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Business Wire
- 2 months ago - Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Business Wire